“AI has the potential to redefine how we discover small molecule medicines, and our team is at the forefront of this revolution,” Genesis CEO Evan Feinberg, Ph.D., said in a Feb. 20 release.

Genesis is pioneering generative and predictive artificial intelligence (AI) technologies to help create therapeutics for challenging targets. Utilizing Genesis’ proprietary AI platform ...

Founded in 2019, Genesis is focused on developing generative and predictive AI technologies, including its proprietary AI platform called Genesis Exploration of Molecular Space, or GEMS ...

The companies have agreed to discover and optimize at least two initial small molecule programs through Genesis’s AI platform, Genesis Exploration of Molecular Space (GEMS). GEMS is designed to ...

Incyte and Genesis will leverage Genesis’ GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough small molecule therapeutics against Incyte-selected targets Incyte ...